Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...

New research suggests that certain medications, including antibiotics, antivirals, vaccines, and anti-inflammatory drugs, may ...

Clinical trials have demonstrated that the drug can delay deterioration by four to six months, targeting the beta-amyloid ...

Former Strictly Come Dancing judge Arlene Phillips took to social media to share an update with fans, admitting she was ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

One London clinic has become the first in Europe to offer the drug privately for an 'eye-watering' annual sum, after the NHS ...